MindMaze formerly Relief Therapeutics develops biopharmaceutical and neurotechnology solutions for neurological and rare diseases.
MindMaze formerly Relief Therapeutics has raised $5.8M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in August 2024.
MindMaze formerly Relief Therapeutics's investors include The Global Emerging Markets Group, SWK Funding.
MindMaze formerly Relief Therapeutics is headquartered in Lausanne, Switzerland.
MindMaze formerly Relief Therapeutics develops biopharmaceutical and neurotechnology solutions for neurological and rare diseases.
MindMaze formerly Relief Therapeutics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MindMaze formerly Relief Therapeutics — Funding & Investors." VCBacked, August 5, 2024, https://www.vcbacked.co/company/mindmaze-formerly-relief-therapeutics. Accessed September 30, 2026.
VCBacked. (2024). MindMaze formerly Relief Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/mindmaze-formerly-relief-therapeutics
{{cite web |title=MindMaze formerly Relief Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/mindmaze-formerly-relief-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated